An Open-Label, 2-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dexamethasone in Transplant-Ineligible Participants With Newly Diagnosed Multiple Myeloma (MagnetisMM6)

Principal Investigator

Dr Jaimal Kothari

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1007002